Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose escalation and expansion studies. These trials are currently underway in the United States and China. Based on preclinical and clinical studies of CDK 4/6 inhibitors, Onconova is also planning a combination trial of narazaciclib with estrogen blockade in advanced endometrial cancer, as well as its clinical study in additional indications.
Onconova’s product candidate rigosertib is being studied in multiple investigator-sponsored studies, including a dose-escalation and expansion Phase 1/2a study of oral rigosertib in combination with nivolumab in patients with KRAS+ non-small cell lung cancer, and a Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa.
Research and Financial Data on Onconova Therapeutics
Please complete the form below to submit your registration requestfor the Luncheon with Onconova Therapeutics, to be held March 28, 2023 in New York, NY, presented by Noble Capital Markets. This meeting is open to qualified investors, and offered at no cost.
A representative will contact you, using the information you provide below, with more details on attending the roadshow.
© 2022 Noble Capital Markets, Inc.
Noble Capital Markets, Inc. Members FINRA, SIPC, MSRB